Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.

4032Background: PD-(L)1 checkpoint blockade has shown clinical benefits in gastroesophageal (GE) cancers. Durvalumab, a selective, high-affinity, engineered human immunoglobulin G1 anti-PD-(L)1 mon...